Company Overview of Peloton Therapeutics, Inc.
Peloton Therapeutics, Inc., an early-stage cancer drug discovery and development company, engages in the development of oncology drugs. The company was incorporated in 2010 and is based in Dallas, Texas.
2330 Inwood Road
Dallas, TX 75235-7323
Founded in 2010
Key Executives for Peloton Therapeutics, Inc.
President and Chief Scientific officer
Compensation as of Fiscal Year 2016.
Peloton Therapeutics, Inc. Key Developments
Peloton Therapeutics, Inc. Presents Clinical Data on First-In-Class Oral HIF-2a Inhibitor in Patients with Advanced Kidney Cancer
Jun 6 16
Peloton Therapeutics, Inc. presented first-in-human Phase 1 clinical data on its lead investigational candidate, PT2385, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago is the first clinical stage antagonist of hypoxia inducible factor-2a (HIF-2a), a transcription factor implicated in the development and progression of kidney and other cancers. Patients with advanced clear cell renal cell carcinoma and at least one prior therapy with a VEGF inhibitor were treated with PT2385 to determine the recommended Phase 2 dose and evaluate safety, pharmacokinetics and pharmacodynamics. Twenty-six patients were enrolled in dose escalation and received PT2385 from 100 to 1,800 mg twice per day. Patients were heavily pretreated prior to study entry, with greater than 50% having four or more prior therapies. Exposure increased with doses up to the 800 mg cohort without a further increase from 800 to 1,800 mg. No dose limiting toxicities were observed at any dose level. Circulating plasma levels of the HIF-2a transcriptional target erythropoietin rapidly decreased with treatment with PT2385 and remained suppressed. Based on safety, pharmacokinetic and EPO pharmacodynamic data, 800 mg twice per day was selected as the recommended Phase 2 dose. An additional 25 patients were enrolled in an expansion cohort at the recommended Phase 2 dose. Among the 51 patients in total, the most common all-grade adverse events (AEs) were anemia, peripheral edema and fatigue. No cardiovascular AEs were noted. To date, one patient had a complete response, three patients had a partial response, and 16 patients had stable disease for 16 or more weeks. 10% of patients remain in this ongoing clinical trial for at least one year.
Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2a Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting
Apr 19 16
Peloton Therapeutics, Inc. presented preclinical data on its lead investigational candidate, PT2385, at the American Association for Cancer Research Annual Meeting in New Orleans, LA. PT2385 is the first clinical stage antagonist of hypoxia inducible factor-2a (HIF-2a), a transcription factor implicated in the development and progression of renal and other cancers. In addition to its direct role in transcription regulation of growth-promoting genes in renal tumors, HIF-2a has been proposed to affect the tumor microenvironment. In a poster titled “PT2385, a Novel HIF-2a Antagonist, Combines with Checkpoint Inhibitor Antibodies to Inhibit Tumor Growth in Preclinical Models by Modulating Myeloid Cells and Enhancing T Cell Infiltration," the combination of PT2385 with antibodies to immune checkpoint control molecules (PD-1, PD-L1, and CTLA4) yielded additive or synergistic efficacy in preclinical tumor models. The combination of PT2385 and immune checkpoint inhibitors is planned for evaluation in clinical trials. 'PT2385 has now been shown to affect the tumor microenvironment, even for tumors that do not express HIF-2a. This potentially broadens the applicability of PT2385 to a larger variety of tumor types, including melanoma and lung cancers, which have been shown to have a strong immunological component.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|